Viral safety and clearance.

Viral safety rests on complementary controls: knowledge of raw and biological sources, testing of cell substrates and process materials, prevention and detection of adventitious agents, and validated process steps that inactivate or remove viruses.¹ The evidence spans development, specialised external laboratories, manufacturing, quality and regulatory commitments, and it usually lives in separate reports.

Seal keeps each viral safety claim connected to the source system, virus model, scaled-down process, study run, calculation, commercial process version and product decision it supports. When a resin changes or a result comes back equivocal, the team can see which claims, batches and products depend on it.

Why teams choose Seal for viral safety

The viral safety argument crosses cell-bank management, raw materials, development, viral-clearance laboratories, analytical methods, manufacturing, validation, quality and CMC, and it usually sits in study reports that are reopened only for a filing or a change. Seal connects those functions so each claim stays linked to the studies, calculations and commercial process version it rests on, and a resin change or equivocal result identifies the claims and batches it affects. The argument can be followed and maintained while the process runs, not only reconstructed. It does not replace scientific experts, biosafety controls or the regulator-agreed strategy; it keeps the evidence behind each conclusion attached to it.

1The strategy defines complementary layers.

Product, expression system, cell substrate, source materials, process, facility, open or closed operations, testing, clearance steps, hold conditions, release requirements and market commitments together form the strategy. Testing and clearance are not interchangeable. The record identifies which risk each layer addresses and what uncertainty remains.

2Source and substrate evidence stays with exact versions.

Source knowledge covers species and tissue origin, passage and adventitious-agent history, animal-origin raw materials, serum or trypsin use, supplier controls and treatments. It stays attached to the exact cell bank, viral seed, material and supplier version.²

Cell-substrate testing is staged. Master and working banks, cells at the limit of in-vitro age, production cells and unprocessed bulk receive their own identity, sterility, mycoplasma, virus and retrovirus testing. Sample provenance, passage, method suitability, invalid results and bank authorisation remain connected.

Each adventitious-agent method, whether a cell-culture indicator assay, PCR panel, reverse-transcriptase assay or sequencing, keeps its target range, blind spots, matrix interference, sensitivity and validation. A negative result is interpreted only within that method’s and sample’s detection capability.

3Clearance models must justify themselves.

Each clearance step, whether low-pH inactivation, solvent or detergent, chromatography, nanofiltration or another operation, is a process object with its mechanism, operating parameters, load composition, capacity, equipment and commercial version. The record distinguishes dedicated clearance steps from steps that contribute incidental removal.

Virus models keep their family, genome, envelope, size, resistance, stock origin, titre and the rationale for their selection, so the panel shows how it challenges each mechanism and represents known or potential contaminants. Scaled-down models compare geometry, resin or membrane, bed height, residence time, load, buffer conditions, flow and pressure against manufacturing. Each difference is justified individually; a model is not accepted merely because it uses a smaller column.

4Study runs preserve material balance and uncertainty.

The protocol follows from the claims the study must support. Kinetics, capacity, robust removal or orthogonality determine the virus panel, worst-case conditions, spike level, sample points, controls, cytotoxicity checks, replicates and acceptance criteria.

Virus stocks and assays remain qualified evidence, with stock identity, passage, titre, storage, assay controls, limit of detection and run validity attributable. Contract-laboratory reports are broken down far enough to reproduce the claim, while the source files and controlled reports are preserved.

Spiking runs reconcile process material, spike amount, dilution, volumes, titres, fractions, hold times, recoveries and losses. Unexplained loss before the challenged step cannot be credited as clearance. Log-reduction calculations keep their input and output titres, volumes, detection limits, handling of non-detects, confidence intervals and reviewer, and individual run results remain distinct from the accepted step claim. Inactivation kinetics and removal capacity answer different questions, so Seal keeps the mechanism-specific evidence rather than presenting every step as one number.

5Step claims are bounded, and totals need a rationale.

A step claim names the virus or virus class, process step and version, operating range, model, accepted runs, reduction factor, uncertainty, limitations, lifecycle conditions and approver. Applying a platform claim to another product requires comparable feedstream and step conditions, and the exclusions stay explicit.

Swipe to see the full diagram →

The overall reduction argument considers mechanism, orthogonality, independence, assay limitations and overlapping effects before step claims are combined. The record shows both the calculated total and the scientific rationale for which claims can be summed.¹

6Commercial batches resolve against the effective claim.

The clearance study is not repeated for each batch. Instead, each batch shows that every validated step operated within its supported state: resin or membrane lot and cycle, actual pH, temperature, time, flow, pressure and load, alarms, interventions, samples and deviations. A step that falls outside its claim boundary, such as a filter pressure excursion, holds the dependent release decision until it has been assessed.

7Signals and changes reassess every dependent claim.

A positive or equivocal adventitious-agent result, control failure, atypical cytopathic effect, raw-material concern or post-study stock issue opens an investigation. The impact traverses source materials, banks, cultures, intermediates, batches, studies, claims, released products and markets, with explicit exclusions.

A change to the cell substrate, a raw material, the process sequence, pH, time, resin, reuse, load, filter area, scale, site, assay or virus stock identifies the bridging or repeat work it requires. Seal separates a change to commercial execution from a change to the scientific model or assay, because they call for different evidence.

8Prove one difficult process end to end.

Follow one monoclonal-antibody process through source and bank risk, unprocessed-bulk testing, virus panel rationale, low-pH inactivation and nanofiltration models, study runs, a censored result, step claims, combined clearance, commercial parameter evidence, a resin change and batch release.

Include assay interference, incomplete spike recovery, an invalid control, kinetic tailing, a filter pressure excursion, a platform claim exclusion and a later supplier concern. The system is ready when it shows which scientific and commercial conclusions remain supported after each one.